Altogether, these results suggest that, in humans, the adverse effects of impaired ghrelin signaling in aging could be mainly due to the decline in UnAG rather than AG and should encourage the design of analogs to UnAG rather than AG to therapeutically treat sarcopenia. This evidence concerns the gene GHRL and sarcopenia.